SI-BONE, Inc. — Third Quarter 2026 Earnings Summary

SI-BONE, Inc. reported worldwide revenue of $55.7 million for the third quarter of 2026, marking a 14.5% increase from the prior year period. The company achieved a net loss of $3.6 million and positive adjusted EBITDA of $3.0 million, while U.S. procedure volumes grew by approximately 20%. Recent operational milestones include the FDA 510(k) clearance for the iFuse Granite Onyx device and the implementation of new MS-DRGs that may increase hospital payments for complex spinal fusion procedures. SI-BONE reaffirmed its 2026 worldwide revenue guidance of $231 million to $233 million and updated its operating expense growth expectation to 10.5%.